ATE552861T1 - Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren - Google Patents
Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahrenInfo
- Publication number
- ATE552861T1 ATE552861T1 AT08729335T AT08729335T ATE552861T1 AT E552861 T1 ATE552861 T1 AT E552861T1 AT 08729335 T AT08729335 T AT 08729335T AT 08729335 T AT08729335 T AT 08729335T AT E552861 T1 ATE552861 T1 AT E552861T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- amphetamine
- stimulants
- production
- polar hydrophilic
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title 1
- 229940025084 amphetamine Drugs 0.000 title 1
- 239000000021 stimulant Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88887007P | 2007-02-08 | 2007-02-08 | |
PCT/US2008/053363 WO2008098151A2 (en) | 2007-02-08 | 2008-02-08 | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE552861T1 true ATE552861T1 (de) | 2012-04-15 |
Family
ID=39591454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08729335T ATE552861T1 (de) | 2007-02-08 | 2008-02-08 | Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren |
Country Status (9)
Country | Link |
---|---|
US (4) | US7772222B2 (de) |
EP (3) | EP2109465B1 (de) |
JP (1) | JP2010518113A (de) |
CN (1) | CN101631566A (de) |
AT (1) | ATE552861T1 (de) |
AU (1) | AU2008213643A1 (de) |
BR (1) | BRPI0807157A2 (de) |
CA (1) | CA2674020A1 (de) |
WO (1) | WO2008098151A2 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
CA2672138A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
CN101631566A (zh) * | 2007-02-08 | 2010-01-20 | 凯姆制药公司 | ***与其它***的极性亲水性前体药物及其制造和使用方法 |
US8614346B2 (en) | 2009-06-19 | 2013-12-24 | Cambrex Charles City, Inc. | Methods and compositions for preparation of amphetamine conjugates and salts thereof |
AU2010275755B2 (en) | 2009-07-22 | 2014-04-24 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US8779191B2 (en) | 2010-12-20 | 2014-07-15 | Cambrex Charles City, Inc. | Methods and compositions for preparing lisdexamfetamine and salts thereof |
US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
HUE032113T2 (en) * | 2011-07-28 | 2017-09-28 | Kempharm Inc | Methylphenidate prodrugs, processes for their preparation and application |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
CA2843390A1 (en) * | 2011-07-29 | 2013-02-07 | Kempharm, Inc. | Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same |
RS56527B1 (sr) | 2011-07-29 | 2018-02-28 | Gruenenthal Gmbh | Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu |
CA2776178A1 (en) | 2012-04-05 | 2013-10-05 | Hydro-Quebec | Ionic compounds |
DK2964185T3 (da) * | 2013-03-05 | 2022-02-14 | Requis Pharmaceuticals Inc | Præparater til behandlingen af søvnrelaterede luftvejslidelser |
WO2014144115A1 (en) * | 2013-03-15 | 2014-09-18 | Shire Llc | Fixed dose combination treatment for schizophrenia |
CA2917136C (en) | 2013-07-12 | 2022-05-31 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CN104833743B (zh) * | 2015-05-18 | 2016-10-26 | 公安部物证鉴定中心 | 一种液质联用分析生物样品中卡西酮、甲卡西酮、4-甲基甲卡西酮的方法 |
US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
WO2018107132A1 (en) | 2016-12-11 | 2018-06-14 | Kempharm, Inc. | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
WO2018160178A1 (en) | 2017-03-01 | 2018-09-07 | Rgenix, Inc. | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof |
EP3609482A4 (de) * | 2017-04-11 | 2021-01-13 | John K. Thottathil | Neuartige alpha-hydroxy-carbonsäure und derivate und andere gras-basierte amid- und imid-prodrugs von amphetaminverbindungen und verwendungen davon |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019136224A1 (en) * | 2018-01-05 | 2019-07-11 | Shire Human Genetic Therapies, Inc. | Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders |
CN109187832B (zh) * | 2018-09-30 | 2021-07-30 | 华润三九医药股份有限公司 | Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法 |
WO2020181000A1 (en) * | 2019-03-06 | 2020-09-10 | Ensysce Biosciences, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
WO2020212952A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
WO2021119316A1 (en) | 2019-12-11 | 2021-06-17 | Rgenix, Inc. | Methods of treating cancer |
CN111410622A (zh) * | 2020-04-13 | 2020-07-14 | 康化(上海)新药研发有限公司 | L-胱硫醚盐酸盐的合成方法 |
EP4211130A1 (de) * | 2020-09-11 | 2023-07-19 | COMPASS Pathfinder Limited | Neue safridaminderivate mit prodrug-eigenschaften |
US20230416219A1 (en) * | 2022-06-25 | 2023-12-28 | Mind Medicine, Inc. | R-mdma crystal forms |
WO2024056678A1 (en) * | 2022-09-12 | 2024-03-21 | Mihkal Gmbh | Novel nootropic prodrugs of phenethylamine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE539185A (de) * | 1954-06-28 | |||
US2881113A (en) * | 1957-01-29 | 1959-04-07 | Ortho Pharma Corp | Therapeutically active compositions containing amphetamines |
US2892753A (en) * | 1957-02-26 | 1959-06-30 | Boehringer Sohn Ingelheim | Central nervous system stimulant |
ES2264226T3 (es) * | 1997-12-22 | 2006-12-16 | Euro-Celtique S.A. | Forma farmaceutica de dosificacion oral que comprende una combinacion de un agonista opioide y naltrexona. |
WO2001013921A1 (en) * | 1999-08-23 | 2001-03-01 | Ockert David M | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
US6525062B2 (en) * | 2000-06-09 | 2003-02-25 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
US6417184B1 (en) * | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
EP1531844B1 (de) | 2002-02-22 | 2014-08-20 | Shire LLC | Neue pharmazeutische verbindungen mit verzögerter freisetzung zur verhinderung von missbrauch kontrollierter substanzen |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
AU2004251647B2 (en) * | 2003-05-29 | 2010-01-14 | Takeda Pharmaceutical Company Limited | Abuse resistant amphetamine compounds |
EP1931357A2 (de) * | 2005-09-13 | 2008-06-18 | Shire LLC | Prodrugs von phentermin |
CA2672138A1 (en) * | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
CN101631566A (zh) * | 2007-02-08 | 2010-01-20 | 凯姆制药公司 | ***与其它***的极性亲水性前体药物及其制造和使用方法 |
-
2008
- 2008-02-08 CN CN200880004216A patent/CN101631566A/zh active Pending
- 2008-02-08 EP EP08729335A patent/EP2109465B1/de active Active
- 2008-02-08 BR BRPI0807157-8A patent/BRPI0807157A2/pt not_active IP Right Cessation
- 2008-02-08 US US12/028,152 patent/US7772222B2/en active Active
- 2008-02-08 JP JP2009549243A patent/JP2010518113A/ja not_active Withdrawn
- 2008-02-08 WO PCT/US2008/053363 patent/WO2008098151A2/en active Application Filing
- 2008-02-08 EP EP11010160.7A patent/EP2433655A3/de not_active Withdrawn
- 2008-02-08 CA CA002674020A patent/CA2674020A1/en not_active Abandoned
- 2008-02-08 AU AU2008213643A patent/AU2008213643A1/en not_active Abandoned
- 2008-02-08 AT AT08729335T patent/ATE552861T1/de active
- 2008-02-08 EP EP11010159.9A patent/EP2433654A3/de not_active Withdrawn
-
2009
- 2009-06-03 US US12/477,616 patent/US20090239949A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/843,173 patent/US20100292337A1/en not_active Abandoned
-
2011
- 2011-02-17 US US13/029,883 patent/US20110213034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2109465B1 (de) | 2012-04-11 |
EP2433654A2 (de) | 2012-03-28 |
EP2109465A2 (de) | 2009-10-21 |
US20100292337A1 (en) | 2010-11-18 |
JP2010518113A (ja) | 2010-05-27 |
AU2008213643A1 (en) | 2008-08-14 |
CN101631566A (zh) | 2010-01-20 |
EP2433655A2 (de) | 2012-03-28 |
CA2674020A1 (en) | 2008-08-14 |
US20090239949A1 (en) | 2009-09-24 |
US20080207757A1 (en) | 2008-08-28 |
BRPI0807157A2 (pt) | 2014-04-29 |
EP2433655A3 (de) | 2013-05-15 |
US20110213034A1 (en) | 2011-09-01 |
WO2008098151A3 (en) | 2008-12-31 |
EP2433654A3 (de) | 2013-05-15 |
WO2008098151A2 (en) | 2008-08-14 |
US7772222B2 (en) | 2010-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE552861T1 (de) | Polare hydrophile prodrugs von amphetamin und anderen stimulantien sowie herstellungs- und verwendungsverfahren | |
ATE509622T1 (de) | Amphetamin-ornithine konjugate sowie herstellungs-und verwendungsverfahren | |
MA52544A (fr) | Instrument d'agrafage chirurgical avec détachement d'arbre d'actionnement | |
ATE548310T1 (de) | Spaltfreudiges klebeband, seine verwendung und verwendung eines werkzeuges zu seiner herstellung | |
TW200716558A (en) | Heteroaroyl-substituted serineamides | |
DE602005023758D1 (de) | Zusammensetzung gegen ein oder mehrere pathogene | |
BRPI0720355B8 (pt) | Composições oftálmicas para o tratamento de presbiopia, bem como o uso das mesmas | |
ATE383740T1 (de) | Schneidelement für gartenwerkzeug | |
WO2011023582A3 (de) | Verwendung von 1,3-diolen als biozide | |
WO2008122375A3 (en) | Insecticidal aryl isoxazoline derivatives | |
WO2008092836A3 (en) | Method for improving plant health | |
ATE530524T1 (de) | Substituierte sulfonamid-derivate | |
WO2009124962A3 (en) | Sulfonamides | |
UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
ITTO20050241A1 (it) | Impianto dentario intraosseo. | |
JP2008519810A5 (de) | ||
UY29980A1 (es) | Nuevas combinaciones de productos activos, comprendiendo un derivado de oximéter y un bis-tiocarbamato, procedimientos de preparación y aplicaciones. | |
EA201000616A1 (ru) | Фунгицидные соединения, способ их получения и их применение для борьбы с вредными грибами, а также содержащие их средства | |
WO2009018551A3 (en) | Therapeutic compounds | |
EP1952691A3 (de) | Verfahren zur Verbesserung der Gesundheit von Pflanzen unter Verwendung eines Triazolopyrimidin-Derivats | |
JP2009143907A5 (de) | ||
FR2897860B1 (fr) | Procede d'optimisation de la marche des unites claus. | |
BRPI0813111A2 (pt) | Derivados de furanose | |
ATE463499T1 (de) | Silizium-harnstoff-azolide, ihre herstellung und verwendung | |
BRPI0922376A2 (pt) | método para produzir di-2-etil-hexanoato de 2,2,4-trimetil-1,3-pentanodiol |